ABSTRACT
Hypertension is the most common of the cardiovascular risk factors. Although its risks have been known for decades, hypertension remains inadequately diagnosed and undertreated. Better understanding of the pathophysiology of hypertension, including the role of the renin-angiotensin system, has led to the development of new approaches for patient management. Compared with traditional antihypertension treatments, angiotensin II receptor antagonists may offer more effective treatment and an improved side effect profile. These agents also may have an important treatment role in other cardiovascular conditions for which ACE inhibitors are commonly prescribed. As clinical trial data are showing, the full potential of these drugs has yet to be determined.
Subject(s)
Angiotensin Receptor Antagonists , Hypertension/drug therapy , Aged , Angiotensin-Converting Enzyme Inhibitors/adverse effects , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Cardiovascular Diseases/etiology , Cardiovascular Diseases/prevention & control , Humans , Hypertension/physiopathology , Middle Aged , Renin-Angiotensin System/drug effects , Renin-Angiotensin System/physiology , Risk FactorsSubject(s)
Kidney Calculi/therapy , Humans , Kidney Calculi/analysis , Kidney Calculi/metabolism , Lithotripsy , RecurrenceABSTRACT
Obviously, a great deal of further research is needed into the effects of latent viral infections. A better understanding of the interaction between psychobiologic disorders and the immune system may also shed light on many of the unanswered questions concerning the role of Epstein-Barr virus (EBV) as well as other latent viruses in clinical disease. At this time, however, there is no convincing evidence that chronic EBV infection is a cause of clinical disease, except in rare instances.
Subject(s)
Infectious Mononucleosis/epidemiology , Antibodies, Viral/analysis , Chronic Disease , Cross-Sectional Studies , Fatigue/etiology , Herpesvirus 4, Human/immunology , Humans , Infectious Mononucleosis/diagnosis , Recurrence , United StatesABSTRACT
In eight patients with end-stage renal disease undergoing chronic hemodialysis moxalactam kinetics were examined. Volume of distribution (Vd), dialysance (Cd), and serum half-life (t1/2) were determined during dialysis with a 1.3 or 1.6 m2 dialyzer. The t1/2 was also determined during the interdialytic period. Vd was 0.25 +/- 0.04 l/kg and Cd was 32.6 +/- 11.7 ml/min and 67 +/- 25.5 ml/min with the 1.3 and 1.6 m2 dialyzers. The t1/2 was 4.8 +/- 0.9 hr using the 1.3 m2 dialyzer and 2.8 +/- 0.6 hr using the 1.6 m2 dialyzer. Moxalactam t1/2 during the interdialytic period was 23.4 +/- 9.6 hr.
Subject(s)
Cephalosporins/blood , Cephamycins/blood , Kidney Failure, Chronic/blood , Renal Dialysis , Adult , Bacterial Infections/complications , Bacterial Infections/drug therapy , Cephamycins/administration & dosage , Female , Humans , Kidney Failure, Chronic/complications , Kinetics , Male , Middle Aged , MoxalactamABSTRACT
A 17-year-old male with systemic lupus erythematosus presented with clinical signs of severe constrictive pericarditis that was confirmed by cardiac catheterization. At surgery, a fibrous pericardium was removed, followed by complete relief of symptoms. Immunopathology of the pericardial tissue revealed deposition of IgG, IgM, and C3. A review of the literature produced only three similar cases. Although rare, constrictive pericarditis, a potentially life threatening complication, may occur in systemic lupus erythematosus presumably with an immunological basis.
